Latest Share Chat

REMOVE ADS

Arecor Therape Share News (AREC)

Arecor Therape Information

Share Price Information for Arecor Therape (AREC)

Share Price is delayed by 15 minutes

Get Live Data

62.50 0.00 (0.00%)

Bid:

60.00

Ask:

65.00

Spread: 5.00 (8.333%)

Market Cap: £23.60m

Last checked at -

Intraday Arecor Therape Share Chart

REMOVE ADS

Arecor Therape News

IN BRIEF: Arecor Therapeutics annual loss widens amid higher costs

Arecor Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Posts total income of GBP3.5 million for 2022, up from GBP1.8 ...

Arecor Therapeutics appoints new chief business officer

(Sharecast News) - Biopharmaceutical company Arecor Therapeutics announced the appointment of Dr Manjit Rahelu as its chief business officer on Wednes...

Arecor Therapeutics begins type-2 diabetes trial

(Sharecast News) - Arecor Therapeutics announced the start of the phase one clinical trial for its ultra-rapid acting insulin candidate 'AT278' on Wed...

Arecor granted three patents in US, India

(Sharecast News) - Biopharmaceutical company Arecor Therapeutics has received patents for its novel formulations of insulin and adalimumab, it announc...

Arecor Therapeutics hails patent protections from India and US

(Alliance News) - Arecor Therapeutics PLC on Thursday celebrated several patent wins in the US and India, as it looks to strengthen its portfolio of p...

Arecor Therapeutics expands existing partnership with development deal

(Alliance News) - Arecor Therapeutics PLC on Tuesday said that it has signed an additional formulation study agreement with its top five global pharma...

TRADING UPDATES: Maintel earnings take hit; Arecor meets expectations

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Arecor ends 2022 in line with forecasts

(Sharecast News) - Biopharmaceutical company Arecor Therapeutics said in an update on Thursday that its financial performance for 2022 was in line wit...